Abstract
Central nervous system primitive neuroectodermal tumors (CNS PNETs) predominantly occur in children and rarely in adults. Because of the rarity of this tumor, its outcomes and prognostic variables are not well characterized. The purpose of this study was to evaluate clinical outcomes and prognostic factors for children and adults with CNS PNET. The records of 26 patients (11 children and 15 adults) with CNS PNET from 1991 to 2011 were reviewed retrospectively. Disease-free survival (DFS) and overall survival (OS) were estimated with the Kaplan–Meier method, and relevant prognostic factors were analyzed. For the cohort, both the 5-year DFS and the OS were 46 %. For pediatric patients, the 5-year DFS was 78 %; for adult patients, it was 22 % (P = 0.004). Five-year OS for the pediatric and adult patients was 67 and 33 %, respectively (P = 0.07). With bivariate analysis including chemotherapy regimen (high dose vs. standard vs. nonstandard) or risk stratification (standard vs. high) and age, the increased risk of disease recurrence in adults persisted. A nonsignificant tendency toward poorer OS in adult patients relative to pediatric patients also persisted. High-dose chemotherapy with stem cell rescue was associated with a statistically significant improvement in OS and a tendency toward improved DFS, although the findings were mitigated when the effect of age was considered. Local recurrence was the primary pattern of treatment failure in both adults and children. Our results suggest that adult patients with CNS PNETs have inferior outcomes relative to the pediatric cohort. Further research is needed to improve outcomes for CNS PNET in populations of all ages.
Similar content being viewed by others
Abbreviations
- CD:
-
Cluster of differentiation
- CCG:
-
Children’s Cancer Group
- CNS:
-
Central nervous system
- DFS:
-
Disease-free survival
- GTR:
-
Gross total resection
- HDCT:
-
High-dose chemotherapy
- HR:
-
Hazard ratio
- OS:
-
Overall survival
- PNET:
-
Primitive neuroectodermal tumor
- NF:
-
Neurofilament
References
Berger MS, Prados MD, Al-Mefty O (2005) Textbook of neuro-oncology. Elsevier Saunders, Philadelphia
Inda MM, Perot C, Guillaud-Bataille M, Danglot G, Rey JA, Bello MJ et al (2005) Genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumours of the central nervous system. Histopathology 47(6):631–637
McCabe MG, Ichimura K, Liu L, Plant K, Backlund LM, Pearson DM et al (2006) High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol 65(6):549–561
Pfister S, Remke M, Toedt G, Werft W, Benner A, Mendrzyk F et al (2007) Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas. Genes Chromosomes Cancer 46(9):839–851
Li M, Lee KF, Lu Y, Clarke I, Shih D, Eberhart C et al (2009) Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 16(6):533–546 Erratum in: Cancer Cell. 2010 Apr 13;17(4):413
Miller S, Rogers HA, Lyon P, Rand V, Adamowicz-Brice M, Clifford SC et al (2011) Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro Oncol 13(8):866–879
Pizer BL, Weston CL, Robinson KJ, Ellison DW, Ironside J, Saran F et al (2006) Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Eur J Cancer 42(8):1120–1128 Epub 2006 Apr 24
Sung KW, Yoo KH, Cho EJ, Koo HH, do Koo H, Shin HJ et al (2007) High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer 48(4):408–415
Cohen BH, Zeltzer PM, Boyett JM, Geyer JR, Allen JC, Finlay JL et al (1995) Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group Randomized Trial. J Clin Oncol 13(7):1687–1696
Russo C, Pellarin M, Tingby O, Bollen AW, Lamborn KR, Mohapatra G et al (1999) Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer 86(2):331–339
Kim DG, Lee DY, Paek SH, Chi JG, Choe G, Jung HW (2002) Supratentorial primitive neuroectodermal tumors in adults. J Neurooncol 60(1):43–52
Reddy AT, Janss AJ, Phillips PC, Weiss HL, Packer RJ (2000) Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 88(9):2189–2193
Timmermann B, Kortmann RD, Kuhl J, Rutkowski S, Meisner C, Pietsch T et al (2006) Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT-SKK87 and HIT-SKK92 trials. J Clin Oncol 24(10):1554–1560
Chintagumpala M, Hassall T, Palmer S, Ashley D, Wallace D, Kasow K et al (2009) A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol. 11(1):33–40 Epub 2008 Sep 16
Johnston DL, Keene DL, Lafay-Cousin L, Steinbok P, Sung L, Carret AS et al (2008) Supratentorial primitive neuroectodermal tumors: a Canadian pediatric brain tumor consortium report. J Neurooncol 86(1):101–108 Epub 2007 Jul 10
Chang CH, Housepian EM, Herbert C Jr (1969) An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93(6):1351–1359
Chawla A, Emmanuel JV, Seow WT, Lou J, Teo HE, Lim CC (2007) Paediatric PNET: pre-surgical MRI features. Clin Radiol 62(1):43–52
Dai AI, Backstrom JW, Burger PC, Duffner PK (2003) Supratentorial primitive neuroectodermal tumors of infancy: clinical and radiologic findings. Pediatr Neurol 29(5):430–434
Rorke LB, Hart MN, McLendon RE (2000) Supratentorial primitive neuroectodermal tumour (PNET). In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer, Lyon, p 141
Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE et al (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7(10):813–820. Erratum in: Lancet Oncol. 2006 Oct;7(10):797
National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). [Internet] Version 4.0. NIH Publication No. 09-5410. Bethesda (MD): U. S. Department of Health and Human Services; 2009 May 28 [updated 2010 Jun 14; cited 2014 May 16]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
Friedrich C, von Bueren AO, von Hoff K, Gerber NU, Ottensmeier H, Deinlein F et al (2013) Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. Neuro Oncol 15(2):224–234 Epub 2012 Dec 7
McBride SM, Daganzo SM, Banerjee A, Gupta N, Lamborn KR, Prados MD et al (2008) Radiation is an important component of multimodality therapy for pediatric non-pineal supratentorial primitive neuroectodermal tumors. Int J Radiat Oncol Biol Phys 72(5):1319–1323 Epub 2008 May 15
Fangusaro J, Finlay J, Sposto R, Ji L, Saly M, Zacharoulis S et al (2008) Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. Pediatr Blood Cancer 50(2):312–318
Albright AL, Wisoff JH, Zeltzer P, Boyett J, Rorke LB, Stanley P et al (1995) Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors: a neurosurgical perspective from the Children’s Cancer Group. Pediatr Neurosurg 22(1):1–7
Dirks PB, Harris L, Hoffman HJ, Humphreys RP, Drake JM, Rutka JT (1996) Supratentorial primitive neuroectodermal tumors in children. J Neurooncol 29(1):75–84
Yang HJ, Nam DH, Wang KC, Kim YM, Chi JG, Cho BK (1999) Supratentorial primitive neuroectodermal tumor in children: clinical features, treatment outcome and prognostic factors. Childs Nerv Syst 15(8):377–383
Mikaeloff Y, Raquin MA, Lellouch-Tubiana A, Terrier-Lacombe MJ, Zerah M, Bulteau C et al (1998) Primitive cerebral neuroectodermal tumors excluding medulloblastomas: a retrospective study of 30 cases. Pediatr Neurosurg 29(4):170–177
Merchant TE, Kiehna EN, Li C, Shukla H, Sengupta S, Xiong X et al (2006) Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma. Int J Radiat Oncol Biol Phys 65(1):210–221 Epub 2006 Feb 10
Mabbott DJ, Barnes M, Laperriere N, Landry SH, Bouffet E (2007) Neurocognitive function in same-sex twins following focal radiation for medulloblastoma. Neuro Oncol. 9(4):460–464 Epub 2007 Aug 17
Picard D, Miller S, Hawkins CE, Bouffet E, Rogers HA, Chan TS et al (2012) Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol 13(8):838–848 Epub 2012 Jun 11
Li MH, Bouffet E, Hawkins CE, Squire JA, Huang A (2005) Molecular genetics of supratentorial primitive neuroectodermal tumors and pineoblastoma. Neurosurg Focus 19(5):E3
Perry A, Miller CR, Gujrati M, Scheithauer BW, Zambrano SC, Jost SC et al (2009) Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol 19(1):81–90 Epub 2008 Apr 29
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lester, R.A., Brown, L.C., Eckel, L.J. et al. Clinical outcomes of children and adults with central nervous system primitive neuroectodermal tumor. J Neurooncol 120, 371–379 (2014). https://doi.org/10.1007/s11060-014-1561-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-014-1561-8